48,830
edits
(+image, more) |
(→IHC: tweak, add refs) |
||
Line 173: | Line 173: | ||
*S-100 +ve - [[schwannoma]]. | *S-100 +ve - [[schwannoma]]. | ||
**+ve in ~80% of fibrous meningiomas. | **+ve in ~80% of fibrous meningiomas. | ||
*CD34 +ve - solitary fibrous tumour. | *CD34 +ve - [[solitary fibrous tumour]]. | ||
**+ve in ~60% of fibrous meningiomas. | **+ve in ~60% of [[fibrous meningiomas]]. | ||
*EMA +ve in ~30% of hemangiopericytoma. | *EMA +ve in ~30% of hemangiopericytoma. | ||
*Claudin-1 - new kid on the block: +ve in meningioma, but low [[sensitivity]]. | *Claudin-1 - new kid on the block: +ve in meningioma, but low [[sensitivity]]. | ||
===Standard work-up (UHN) | ===Standard work-up (UHN)=== | ||
*Ki-67 >5-10% - predicts re-occurrence. | *Ki-67 >5-10% - predicts re-occurrence.<ref>Croul, SE. 8 November 2010.</ref> | ||
*PR (progesterone receptor) +ve in | *PR (progesterone receptor) +ve in > 80% of meningiomas.<ref>{{Cite journal | last1 = Takei | first1 = H. | last2 = Buckleair | first2 = LW. | last3 = Powell | first3 = SZ. | title = Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. | journal = Neuropathology | volume = 28 | issue = 1 | pages = 62-8 | month = Feb | year = 2008 | doi = 10.1111/j.1440-1789.2007.00852.x | PMID = 18021195 }}</ref> | ||
**Loss of PR staining predicts recurrence. | |||
**Strong association with tumour grade:<ref name=pmid22616825>{{Cite journal | last1 = Tao | first1 = Y. | last2 = Liang | first2 = G. | last3 = Li | first3 = Z. | last4 = Wang | first4 = Y. | last5 = Wu | first5 = A. | last6 = Wang | first6 = H. | last7 = Lu | first7 = Y. | last8 = Liu | first8 = Z. | last9 = Hu | first9 = G. | title = Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. | journal = Br J Neurosurg | volume = | issue = | pages = | month = May | year = 2012 | doi = 10.3109/02688697.2012.685780 | PMID = 22616825 }}</ref> | |||
***Low WHO grade tumours usu. +ve. | |||
***High WHO grade tumours usu. -ve. | |||
==See also== | ==See also== |
edits